Search

  1. ProQR Announces First Quarter 2025 Operating and Financial Results

    Press release

    Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Strengthened leadership with appointments of Chief Financial Officer and Chief

  3. ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event

    Press release

    … with Eli Lilly that is exclusively focused on RNA editing, leading IP position, and cash runway into mid-2026, ProQR is … 50% editing reported in the nervous system of NHP in vivo Additionally, ProQR’s Axiomer technology achieves increased … “The progress the field and ProQR are making in optimizing ADAR for therapeutic use is exciting,” said Peter Beal, PhD, …

    Thumbnail of the R&D event 2023 presentation

  5. ProQR Announces First Quarter 2023 Operating and Financial Results

    Press release

    … Results Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and … areas Strength of intellectual property estate and leading IP position supported with successful defense of opposition against a key Axiomer patent protecting ADAR-mediated RNA editing Well-capitalized with €139 M, in …

  9. ProQR Presents in vivo Proof of Concept Data for the Axiomer® RNA Editing Platform Technology

    Press release

    … Editing Oligonucleotides (EONs) recruit endogenous ADAR to make single nucleotide changes to RNA in a highly … Gerard Platenburg, Chief Innovation Officer at ProQR added, “We are the first to show evidence of RNA editing … an endogenously expressed RNA editing system called ADAR, which it can direct to change an Adenosine (A) to an …